Manejo terapéutico de la hiperprolactinemia. Therapeutic management of hyperprolactinemia. Visits. J M. Cabezas Agrícolaa, J. Cabezas-Cerratoa. Num. Pages Manejo clínico de las hiperprolactinemias. Clinical management of hyperprolactinemia. Visits. Download PDF. La frecuencia de hiperprolactinemia en esta entidad es del 13 al 59% y los . Artículo. B. Farzati,G. Mazziotti,G. Cuomo,M. Ressa,F. Sorvillo,G. Amato.
|Published (Last):||16 August 2011|
|PDF File Size:||1.81 Mb|
|ePub File Size:||9.40 Mb|
|Price:||Free* [*Free Regsitration Required]|
Malignant prolactinoma should be suspected in patients with no response to drug treatment or recurrence after surgery.
The Endocrine System and the Heart: A Review
J Rheumatol, 33pp. Abstract Hyperprolactinemia can be due to both prolactin-secreting pituitary adenomas prolactinomas and nonfunctioning sellar tumors so called “pseudoprolactinomas”. Dopamine agonists have been in clinical use for many years and remain the cornerstone for therapy of prolactinomas. This articu,o has been cited by other articles in PMC.
[Current diagnosis and treatment of hyperprolactinemia].
The primary role of ACTH is to regulate adrenal cortisol secretion. See text for considerations on MRI and visual field monitoring and treatment discontinuation in patients with microprolactinoma and macroprolactinoma. Therapeutic management of hyperprolactinemia.
Footnotes Source of Support: Scanning should be repeated only if symptoms reappear or exacerbate. Subsequently, repeat testing should be considered if it is affected. Microadenoma with hyperprolactinemia Medical management can be undertaken for a period ranging from 18 months to 6 or more years.
Subscriber If you already have your login data, please click here. Examination may be performed after hyperprolactinemia is detected and secondary causes have been ruled out, or may be requested for other reasons headache, campimetric changes, etc. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: This has not been established as being required for microprolactinoma unless PRL increases or new symptoms occur. Should macroprolactin be measured in all hyperprolactinaemic sera?.
Although the cumulative risk dose has not yet been established, we suggest that performing routine echocardiographic controls in the first few years of treatment in patients receiving cabergoline 1—2 mg weekly is not indispensable3 unless advised by the presence of coexistent clinical factors. Indications for surgery in prolactinomas. Nil Conflict of Interest: Studies were conducted with cabergoline, but no clear evidence of either an association at the standard dose or a potential impact of the total cumulative dose was found, which may be important in treatments lasting decades.
Osteoporosis methodology group and the osteoporosis research advisory group. Advances in the treatment of prolactinomas. N Engl J Med,pp.
Alteraciones endocrinas en la esclerosis sistémica | Reumatología Clínica
Temozolomide has been used with encouraging results in several cases of PRL-secreting pituitary carcinomas 49 hiperprolacrinemia do not respond to treatment with dopamine agonists and in benign but invasive prolactinomas. Data from animal studies suggest that PTH has trophic effects on cardiomyoctes that results in hypertrophy.
Pergolide was withdrawn from the market for this reason. It is administered twice daily; treatment is started with 0. As with other subjects related to neuroendocrinology, it should be taken into account that little high-quality evidence is available in many aspects. Patients who are intolerant or fail to respond to one agent hiperporlactinemia do well with another.
Diagnostic evaluation should include measurements of serum total and ionized calcium, albumin, phosphorus, magnesium, creatinine, intact PTH, and hydroxyvitamin D.
Si continua navegando, consideramos que acepta su uso. This may be due to hydrolysis of the lysergic acid part of the molecule. Pitfalls in Distinguishing True Prolactinomas from “Pseudoprolactinomas”. Clin Endocrinol Oxf61pp. The journal fully hiperprolactinemja the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Osteopenia in systemic sclerosis: In postmenopausal women, the clinical signs are mainly due to the mass effect of the adenoma.
The possible coexistence of other physiologic, pathologic or iatrogenic cause of hyperprolactinemia, as well as hiperprolaftinemia artifacts “hook effect” and the presence of prolactin variants devoid of biological activity macroprolactins can give origin to pitfalls.
From Monday to Friday from 9 a.